Immune Cell Therapy �Patient-Customized Cancer Therapy� by qLu36Hx

VIEWS: 1 PAGES: 25

									“Above all else, guard your heart, it is the wellspring of life”
                       Proverbs 4:23
                                                                                                   2




     Forward Looking Statement
         Statements contained in this presentation that are not historical facts are forward-looking
statements, as the term is defined in the Private Securities Litigation Reform Act of 1995. You
can identify these forward-looking statements by the use of words such as “expects,” “plans,”
“estimates,” “projects,” “promises,” “intends,” “believes,” and similar expressions that do not
relate to historical matters. Such forward-looking statements are subject to risks and
uncertainties that can cause actual results to differ materially from those currently anticipated,
due to a number of factors, which include, but are not limited to, to identify strategic partners or,
if identified, the inability to enter into an acceptable agreement with such strategic partners and
successfully concluding the development and regulatory processes. All forward-looking
statements in this presentation are made as of the date of this presentation, based upon
information known to management as of the date hereof. VasoGenix assumes no obligation to
update or revise any of its forward-looking statements even if experience or future changes show
that indicated results or events will not be realized.
                                               3




    Significance of Heart Failure
   #1 Patient Diagnosis Over Age 65
   #1 Cause of Death Over Age 65
   #1 Hospital Expense at $15 Billion
   Over 1 Million Hospitalizations Annually




80% Over Age 65 Will Die of Heart Failure
                                              4




          Current Treatments
   Diuretics to Remove Excess Fluids
   ACE Inhibitors for Hypertension
   Beta Blockers to Slow Heart Rate
   Vasodilators to Reduce Heart Pumping Effort




    Multiple Drugs Required for Treatment
                                                   5




          Goals of Our Therapy
   Reduce Hospital Readmission Rate by Half
   Reduce Annual Hospital Costs by $6 Billion
   Eliminate 400,000 Readmissions
       Save $16,000 per Hospital Visit

   Provide Longer and Healthier Quality of Life
                                                     6




Calcitonin Gene Related Peptide
                       (Human CGRP)

                  Significant Body of Research
                  Clinical Profile
                      Improves Cardiac Function
                      Maintains Kidney Blood Flow
 Calcitonin
Gene Related          Cardioprotective
  Peptide
                      Reduces Cardiac muscle
                       Inflammation

                  Established Human Safety
                   Profile
                                                              7




 Human CGRP Agonist Analogs
                   IP protected
                   Synthesized, characterized, tested
                   In-vitro, In-vivo bio-activity
                    confirmation ≥ human αCGRP
                   Clinical Profile Expectations
CGRP Agonists
                       ≥ to CGRP
                       Differentiation of effects based on
                        structure
                       Tailorable to indication
Could Become a Platform Technology
                                               8



            Clinical Expectations
         Optimized Dose of 0.008 µg/kg/min

Cardiac Output                        ⇧      72%
Left Ventricular Stroke Index         ⇧      60%
Pulmonary Capillary Wedge Pressure    ⇩      37%
Pulmonary Vascular Resistance         ⇩      22%
Neurohormonal Response                ⇨      0%
Renal Blood Flow                      ⇧      34%
Glomerular Filtration Rate            ⇧      43%
Heart Rate                            ⇨      0%

Source: Anand 1991 & Shekhar 1991
                                            9




       Product #1: In-Hospital
   Provides Combined Benefits of Several
    Drugs
   IV Administration
   Stabilization of Symptoms
   Reduce Hospitalization Time
                                            10




     Product #2: Post-Hospital
   Controlled Release Drug
   Easy to Administer
   Requires Only Periodic Administration
   Continuous Treatment
                                                          11




        Product #2: Post-Hospital
   First 7 days after discharge or out-patient
       Greatest unmet need in heart failure treatment

   Cardiologists need treatment options
       CGRP analog can meet the need

   CGRP recognized as having the right
    therapeutic qualities to meet this need
       Stabilize heart failure symptoms and reduce re-
        hospitalizations

            Major Market Differentiation
                                            12




           Intellectual Property
   13 US and Foreign Patent Applications
     Heart Failure
     Acute MI
     Renal Insufficiency
     Controlled Release
     CGRP and CGRP Agonist Analogs

   5 Patents In Process
       New Drug Applications



            Heart and Kidney Focused
                                                                       13




    VasoGenix Leadership Team
   Board of Directors
     Lee Southard, PhD – Chairman
     Richard Dunn, PhD – Former Sr. VP Drug Delivery Research, QLT/Atrix
      Laboratories
     Donald Braun, PhD – Vice President, Clinical Research, Cancer
      Treatment Centers of America
     Thomas Noffsinger, PhD – Former Assistant Vice-Chancellor, KUMC
      Research Institute
   Scientific Advisory Board
   Clinical Research Steering Committee



Experience from Drug Discovery to FDA Approval
                                                              14




                         Management
 Dr. G. Lee Southard
 President & Chief Executive Officer
    Atrix Laboratories, Inc.
         Founder, President, CEO & CSO 1987–1998
         Increased Share Price from $.50 to $29
         Company Sold to QLT Inc. for $855 million
    Vipont Pharmaceuticals, Inc.
         Co-founder, VP R&D 1981-1986
         Increased Share Price from $.50 to $15
         Company Sold to Colgate-Palmolive for $94 million
    Big Pharma Executive Experience
         Eli Lilly
         Johnson & Johnson



10 FDA Approved Drug and Device Products
                                               15




                  Management
Jeff Southard
Co-Founder & Vice President Drug Development
   6 New Drugs to Market
   3 New Medical Devices
   5 Patents Issued, 3 Patents Pending
   13 Publications and Presentations
   Big Pharma and CRO Experience



20 Years Drug Discovery and Development
                                                      16




            Using Specialists
              Partners in Development

   Pre-Clinical Testing
     Xenometrics
     Acceleration, LLC
     GEL Analytics, Inc.
     Fleishman-Hillard
     Kidney Institute of Kansas University Medical
      Center (KUMC)
     Mid America Cardiology Associates at KUMC
                                              17




Pre-Clinical Research
              University of Kansas Hospital
             Center for Advanced Heart Care




               The Kidney Institute at the
           University of Kansas Medical Center


                  NIDDK Training Center



  CGRP Analog Profiling
                                                            18




                 Using Specialists
                   Partners in Development

   Research Collaborations
       Tulane University School of Medicine
            CGRP Protects Heart Cells from Death During
             Heart Attack Heart Failure Conditions
             (American Heart Association 2005)

       Cleveland Clinic Lerner Research Institute
            CGRP Receptors in Heart Failure Patients Are
             Upregulated 38%
             (American Heart Association 2007)
                                           19




                Using Specialists
                 Partners in Development

   Manufacturing
       New England Peptides, LLC
       PolyPeptide Laboratories, Inc.

   Regulatory Consulting
       Beckloff Associates, Inc.
       LIPICKY, LLC

   Clinical Testing
       Cleveland Clinic
       Averion
                                             20




      Clinical Trials

                   Heart and Vascular Institute




Proof of Concept and Phase I/II
                                                                    21




        Development Timeline
               Yr.1   Yr.2   Yr.3   Yr.4    Yr.5    Yr.6   Yr.7   Yr.8
Non-clinical   
       IND
 Phase I/II
   Exit Opp
  Phase III
       NDA
   Revenue


                                              Exit
                                           Opportunity
                                               1



         Focused on Exit Opportunity
                                                      22




              Financing to Date
   Raised $4.5 Million
       Synthesis and Characterization of New Analogs of
        CGRP In-vitro and in-vivo
       Established clear market differentiation
       Initial Development of Controlled Release
       Pre-IND Meeting with FDA
       Strengthened Intellectual Property
       Established Development Plan
                                       23




                  Summary
   Exciting New Series of Compounds
   IP Strong
   Clear HF market application
   Revenue Projections Excellent
   Developmental Partners The Best
   Two Years to Clinic
   Four years to Exit
                      Revenue Projection
($ million)                          Year 1   Year 2   Year 3   Year 4   Year 5   Year 6


In-Hospital Drug                       $58     $127     $210     $308     $423     $558


CRD – Initial Visit Patients            43       94      156      228      314      415


CRD – Repeat Visit Patients             85      186      301      435      589      766


CRD – VasoGenix Recurring Patients        -      64      156      268      399      551


  Total Treatment Revenue              186      471      823    1,239    1,725    2,290


License                               10%      10%      10%      10%      10%      10%


  Total Royalty                        $19      $47      $82     $124     $173     $229
               VasoGenix Pharmaceuticals
                  8527 Bluejacket Street
                  Lenexa, Kansas 66214

Dr. G. Lee Southard           Jeff Southard
southardl@earthlink.net       jsouthard@vasogenix.us

								
To top